Ondine Biomedical Inc (OBI) - Net Assets
Based on the latest financial reports, Ondine Biomedical Inc (OBI) has net assets worth GBX3.49 Million GBX (≈ $424.53 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX14.40 Million ≈ $1.75K USD) and total liabilities (GBX10.91 Million ≈ $1.33K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OBI strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX3.49 Million |
| % of Total Assets | 24.23% |
| Annual Growth Rate | 3.84% |
| 5-Year Change | -88.23% |
| 10-Year Change | 1149.77% |
| Growth Volatility | 700.59 |
Ondine Biomedical Inc - Net Assets Trend (2001–2025)
This chart illustrates how Ondine Biomedical Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see OBI market cap.
Annual Net Assets for Ondine Biomedical Inc (2001–2025)
The table below shows the annual net assets of Ondine Biomedical Inc from 2001 to 2025. Also explore Ondine Biomedical Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX3.49 Million ≈ $424.53 |
-49.26% |
| 2024-12-31 | GBX6.88 Million ≈ $836.73 |
+229.83% |
| 2023-12-31 | GBX2.08 Million ≈ $253.68 |
-82.09% |
| 2022-12-31 | GBX11.64 Million ≈ $1.42K |
-60.74% |
| 2021-12-31 | GBX29.66 Million ≈ $3.61K |
+187.67% |
| 2020-12-31 | GBX-33.83 Million ≈ $-4.12K |
-29.74% |
| 2019-12-31 | GBX-26.07 Million ≈ $-3.17K |
-45.68% |
| 2018-12-31 | GBX-17.90 Million ≈ $-2.18K |
-173.34% |
| 2017-12-31 | GBX-6.55 Million ≈ $-796.70 |
-2445.38% |
| 2010-12-31 | GBX279.19K ≈ $33.97 |
-78.15% |
| 2009-12-31 | GBX1.28 Million ≈ $155.48 |
-4.44% |
| 2008-12-31 | GBX1.34 Million ≈ $162.71 |
-87.67% |
| 2007-12-31 | GBX10.84 Million ≈ $1.32K |
-34.64% |
| 2006-12-31 | GBX16.59 Million ≈ $2.02K |
+0.53% |
| 2005-12-31 | GBX16.50 Million ≈ $2.01K |
+7350.48% |
| 2003-08-31 | GBX-227.62K ≈ $-27.70 |
-58.87% |
| 2002-08-31 | GBX-143.28K ≈ $-17.43 |
-110.28% |
| 2001-08-31 | GBX1.39 Million ≈ $169.63 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ondine Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31470499700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX288.54 Million | 8269.56% |
| Other Comprehensive Income | GBX19.74 Million | 565.62% |
| Other Components | GBX10.54 Million | 302.09% |
| Total Equity | GBX3.49 Million | 100.00% |
Ondine Biomedical Inc Competitors by Market Cap
The table below lists competitors of Ondine Biomedical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Contagious Gaming Inc
V:CNS
|
$680.25K |
|
Kodal Minerals PLC
LSE:KOD
|
$681.68K |
|
Tinybuild Inc
LSE:TBLD
|
$681.88K |
|
OPTIMI HEALTH CORP.
F:8BN
|
$683.89K |
|
Onward Opportunities Ltd
LSE:ONWD
|
$678.69K |
|
CaNickel Mining Ltd
V:CML
|
$678.54K |
|
Microlise Group PLC
LSE:SAAS
|
$677.15K |
|
Sunindo Adipersada Tbk Pt
JK:TOYS
|
$672.68K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ondine Biomedical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,877,000 to 3,489,199, a change of -3,387,801 (-49.3%).
- Net loss of 29,588,760 reduced equity.
- New share issuances of 25,981,000 increased equity.
- Other comprehensive income increased equity by 19,735,762.
- Other factors decreased equity by 19,515,803.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-29.59 Million | -848.01% |
| Share Issuances | GBX25.98 Million | +744.61% |
| Other Comprehensive Income | GBX19.74 Million | +565.62% |
| Other Changes | GBX-19.52 Million | -559.32% |
| Total Change | GBX- | -49.26% |
Book Value vs Market Value Analysis
This analysis compares Ondine Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1432.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 10.45x to 1432.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-08-31 | GBX1.03 | GBX10.75 | x |
| 2002-08-31 | GBX-0.11 | GBX10.75 | x |
| 2003-08-31 | GBX11.97 | GBX10.75 | x |
| 2005-12-31 | GBX0.41 | GBX10.75 | x |
| 2006-12-31 | GBX0.35 | GBX10.75 | x |
| 2007-12-31 | GBX0.20 | GBX10.75 | x |
| 2008-12-31 | GBX0.02 | GBX10.75 | x |
| 2009-12-31 | GBX0.01 | GBX10.75 | x |
| 2010-12-31 | GBX0.00 | GBX10.75 | x |
| 2017-12-31 | GBX-0.03 | GBX10.75 | x |
| 2018-12-31 | GBX-0.09 | GBX10.75 | x |
| 2019-12-31 | GBX-0.13 | GBX10.75 | x |
| 2020-12-31 | GBX-0.17 | GBX10.75 | x |
| 2021-12-31 | GBX0.15 | GBX10.75 | x |
| 2022-12-31 | GBX0.06 | GBX10.75 | x |
| 2023-12-31 | GBX0.01 | GBX10.75 | x |
| 2024-12-31 | GBX0.03 | GBX10.75 | x |
| 2025-12-31 | GBX0.01 | GBX10.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ondine Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -848.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1115.53%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 4.13x
- Recent ROE (-848.01%) is below the historical average (-260.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -5.26% | 0.00% | 0.00x | 1.04x | GBX-212.71K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-1.52 Million |
| 2003 | -0.52% | 0.00% | 0.00x | 0.00x | GBX-1.70 Million |
| 2005 | -51.74% | 0.00% | 0.00x | 1.05x | GBX-10.19 Million |
| 2006 | -72.10% | -738.91% | 0.09x | 1.11x | GBX-13.62 Million |
| 2007 | -121.30% | -819.56% | 0.12x | 1.20x | GBX-14.24 Million |
| 2008 | -767.99% | -1125.69% | 0.31x | 2.20x | GBX-10.40 Million |
| 2009 | -359.59% | -470.77% | 0.37x | 2.05x | GBX-4.72 Million |
| 2010 | -1166.60% | -212.46% | 0.60x | 9.08x | GBX-3.28 Million |
| 2017 | 0.00% | -1561.65% | 0.07x | 0.00x | GBX-5.78 Million |
| 2018 | 0.00% | -4465.42% | 0.08x | 0.00x | GBX-14.87 Million |
| 2019 | 0.00% | -3014.01% | 0.16x | 0.00x | GBX-11.38 Million |
| 2020 | 0.00% | -908.49% | 0.68x | 0.00x | GBX-12.89 Million |
| 2021 | -168.88% | -1949.59% | 0.08x | 1.15x | GBX-53.05 Million |
| 2022 | -166.37% | -3036.36% | 0.04x | 1.42x | GBX-20.54 Million |
| 2023 | -691.22% | -1198.00% | 0.21x | 2.75x | GBX-14.62 Million |
| 2024 | -277.71% | -932.06% | 0.16x | 1.86x | GBX-19.79 Million |
| 2025 | -848.01% | -1115.53% | 0.18x | 4.13x | GBX-29.94 Million |
Industry Comparison
This section compares Ondine Biomedical Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,096,004
- Average return on equity (ROE) among peers: -345.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ondine Biomedical Inc (OBI) | GBX3.49 Million | -5.26% | 3.13x | $679.55K |
| 4BASEBIO UK SOCIETAS (4BB) | $-492.00K | 0.00% | 0.00x | $1.06 Million |
| Aptamer Group PLC (APTA) | $304.00K | -2577.63% | 8.06x | $106.65K |
| Arecor Therapeutics PLC (AREC) | $6.45 Million | 10.29% | 0.26x | $401.97K |
| Avacta Group PLC (AVCT) | $14.00K | -764.29% | 1.36x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $2.72 Million | -40.97% | 0.11x | $14.84K |
| Bioventix (BVXP) | $-71.00K | 0.00% | 0.00x | $985.36K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $1.67 Million | -80.55% | 0.34x | $77.17K |
| CRISM Therapeutics Corporation (CRTX) | $15.21 Million | -4.50% | 0.05x | $93.94K |
| Fusion Antibodies PLC (FAB) | $323.00K | 0.00% | 1.18x | $154.88K |
| Faron Pharmaceuticals Oy (FARN) | $-15.16 Million | 0.00% | 0.00x | $485.05K |
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfecti… Read more